about
Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancerExome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomasMultigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.Reporting tumor molecular heterogeneity in histopathological diagnosis.DNA qualification workflow for next generation sequencing of histopathological samples.Next-generation sequencing for genetic testing of familial colorectal cancer syndromes.Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis.BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencingA Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic CharacteristicsPTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.New genomic landscapes and therapeutic targets for biliary tract cancers.Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma.Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.Genomic Characterization of Biliary Tract Cancers Identifies Driver Genes and Predisposing Mutations.Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours.Whole-genome landscape of pancreatic neuroendocrine tumours.Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations.Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression.Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy.High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers.Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma.Centrosome Linker-induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal CancersMolecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreasNext-Generation Histopathologic Diagnosis: A Lesson From a Hepatic CarcinosarcomaCollapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell SecretomeERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistanceUnmasking the impact of Rictor in cancer: novel insights of mTORC2 complexMultigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patientsTargeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological modelGlioblastoma with tumor-to-tumor metastasis from lung adenocarcinomaMetformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLCComparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate CancerDiffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testingComparative Lesions Analysis Through a Targeted Sequencing ApproachMutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestineGene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic AlterationsPatterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?
P50
Q30854226-B0D00AF6-7645-4173-9D07-E799CCDE328CQ33581027-781C91BB-D40B-4C09-B804-0610C2E3250CQ33757122-03BF2422-860A-40B5-B76C-8238F6FC8432Q34050798-7ADA5297-7DB5-4C67-847D-FD470BC4668BQ34769357-1750F528-5A4D-442D-94DB-D69650C36A05Q35986817-DD401EA4-5152-46B2-8A74-C8D0A7A397CAQ36670779-72DF5B46-6DFD-426C-9D8E-C0C060AEF244Q36738744-62B6032B-583C-4548-B97E-4544952BEEEBQ37097257-1DBF1B6F-417D-438C-ADD8-D5B79557DC6DQ37655023-99D85078-82F9-4CD9-9BF2-DF45A4684760Q38681183-27585577-5E7D-45D1-895E-44B45B68DEF5Q41981114-86F5E7A0-FA78-4906-9643-4836C9942353Q47429093-7903C79E-F6FA-42B0-B919-411832591971Q48127891-07EE6FC6-E6A2-41FA-806C-23D4852C69EBQ48526884-9F154544-B06D-4828-9168-DE2F3DA53688Q49720507-1C1AC720-EC04-47BE-96CD-ECED596BA729Q51137102-0DFE3877-989B-4922-8D5A-6513BDF7DC15Q51525871-D1038ADC-D8FD-40B7-A13D-B33202FD342EQ52668218-839C280A-7E31-4D00-B063-D8A22E00855EQ53224958-3AF3FF9F-A413-44D0-BB74-17E19E4736F6Q54298122-88099071-3436-442B-ADB3-B511619AA0E3Q54352691-CDC1009D-4310-4997-AEC0-C63756193057Q54542254-4E8A8D09-FB50-4C05-A42A-F9EF076ED098Q55523920-66610AE2-6952-4080-93CC-D39194AED8E5Q56381555-C63CB0FD-6B9B-470B-9F79-21CD9B3719D4Q57284937-AD3558B7-F217-49DC-A715-DE0CD8D75D6CQ57422624-8ADDD65B-5B64-4C9E-8C1C-6DC058E725A9Q61802863-F3082313-3AF2-45A3-B082-D8FA49416BB8Q61884085-547D5919-6482-4DEE-A710-83D3E476F983Q89338002-473F5F35-94F4-4CDF-B463-63A123AD8D48Q89534412-ADA688AC-8A45-4F67-AE18-132114D8319FQ89576846-61AC7289-7289-4917-8B86-CA71967BA254Q90118150-F239F40A-F8E7-4D6D-8596-CE3D6211AFF1Q91159351-B6B97881-D3DE-413D-91CB-6145641FCF6EQ91244118-2B08C403-3B63-48BA-9CC3-E4D5FE103149Q91407899-310025E4-EEAF-435B-98E3-8583BBBAB00EQ91425900-7CE56C2D-990D-49A1-A807-281FE49E20A2Q91468693-5C2FC7BF-B253-4AB7-9177-F9E316EDC79AQ91993848-6FB777D5-7BC8-4FAC-B52A-D099153A9A30Q92252647-31BA2693-1CED-4C87-9610-027D7E31B7BF
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michele Simbolo
@ast
Michele Simbolo
@en
Michele Simbolo
@es
Michele Simbolo
@nl
Michele Simbolo
@sl
type
label
Michele Simbolo
@ast
Michele Simbolo
@en
Michele Simbolo
@es
Michele Simbolo
@nl
Michele Simbolo
@sl
prefLabel
Michele Simbolo
@ast
Michele Simbolo
@en
Michele Simbolo
@es
Michele Simbolo
@nl
Michele Simbolo
@sl
P106
P1153
55760291600
P31
P496
0000-0002-0866-4499